Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
The European Hematology Association (EHA)
The European Hematology Association (EHA)
The
European Hematology Association
(
EHA
) is a non-governmental and not-for-profit membership organization that is guided by its mission to promote excellence in patient care, research, and education in hematology.
Outcomes Associated with Conventional Salvage Therapy in Patients with Refractory or Relapsed AML and IDH1/IDH2 Mutations
EHA 2016
,
EHA 2016 – Leukemia
Somatic mutations affecting isocitrate dehydrogenase 1 (
IDH1
) or 2 (
IDH2
) genes are found in 15% to 20% of patients with acute myeloid leukemia (AML), with incidence increasing in older patients. These mutated enzymes represent therapeutic targets, and selective inhibitors of
IDH1
and
IDH2
are in early-phase development. This study assessed differences in outcomes for patients with relapsed AML and
IDH1/IDH2
mutations.
Read More ›
Higher-Dose Daunorubicin Is Effective in Patients with AML Who Harbor FLT3-ITD Mutations
EHA 2016
,
EHA 2016 – Leukemia
Anthracycline and Ara-C have been standard induction agents for acute myeloid leukemia (AML) for 30 years. Several trials comparing 90 mg/m
2
of daunorubicin with 45 mg/m
2
have found either overall benefits or benefit in specific patient subgroups, such as
FLT3-ITD
–mutant patients. This analysis confirms the value of higher-dose daunorubicin after a median follow-up of 2+ years.
Read More ›
Overall Survival Benefit in Relapsed and Refractory B-Cell ALL Patients Receiving Inotuzumab Ozogamicin
EHA 2016
,
EHA 2016 – Leukemia
Inotuzumab ozogamicin (InO), a humanized anti-CD22 antibody conjugated to calicheamicin, has demonstrated superior responses compared with chemotherapy in patients with relapsed and refractory acute lymphoblastic leukemia (ALL) in a phase 3 trial known as INO-VATE. In this late-breaking presentation, researchers report overall survival and progression-free survival findings for InO relative to chemotherapy.
Read More ›
CD19 CAR T Cells Induce Potent Responses and Control CNS Leukemia in Relapsed ALL
EHA 2016
,
EHA 2016 – Leukemia
Chimeric antigen receptor (CAR)-modified T cells are emerging as an effective and safe therapy for children and young adults with acute lymphoblastic leukemia (ALL). This study assesses CD19 CAR T cells in pediatric patients with ALL, including patients with a history of central nervous system (CNS) involvement.
Read More ›
Ibrutinib plus Bendamustine and Rituximab (BR) in Previously Treated CLL/SLL: 2-Year Follow-Up Data from the HELIOS Study
EHA 2016
,
EHA 2016 – Leukemia
Ibrutinib, an inhibitor of Bruton’s tyrosine kinase, is approved for use as monotherapy in patients with treatment-naïve and relapsed chronic lymphocytic leukemia (CLL). Studies of ibrutinib in combination with other agents are underway. Follow-up data from a large phase 3 study of ibrutinib + BR versus BR in relapsed CLL have now reached the 2-year point.
Read More ›
Acalabrutinib, a Second-Generation BTK Inhibitor, Is Active in Previously Untreated CLL
EHA 2016
,
EHA 2016 – Leukemia
Acalabrutinib is a second-generation inhibitor of Bruton’s tyrosine kinase (BTK) that is currently being evaluated in patients with previously untreated and relapsed chronic lymphocytic leukemia (CLL), as well as other hematologic malignancies. Researchers report phase 1/2 study results for acalabrutinib, including overall response rates, rates of treatment-related lymphocytosis, bleeding risk, and other safety details.
Read More ›
Ibrutinib Results in Robust Clinical Activity and Survival Outcomes in Difficult-to-Treat CLL Populations
EHA 2016
Patients with deletion 17p chronic lymphocytic leukemia (CLL) have aggressive disease and poor outcomes with chemoimmunotherapy. Ibrutinib, a once-daily therapy that inhibits Bruton’s tyrosine kinase, is approved for previously untreated patients with CLL, including patients with deletion 17p. This cross-study analysis of efficacy and tolerability outcomes for ibrutinib reports 2+-year data in this high-risk subset of patients.
Read More ›
Page 5 of 5
1
2
3
4
5
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us